Equity Profile

BBIO

BridgeBio Pharma, Inc.

Health CareBiotechnology$16.3B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing innovative therapies for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and meet market demand.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing innovative therapies for genetic diseases. With a market cap of $16 billion, it operates in the health care sector, which is seeing increased interest due to advancements in personalized medicine and genetic research.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the upcoming earnings report, especially given the company's recent history of missing EPS estimates. Analysts are looking for signs of improvement in both profitability and revenue.

Bull Case

If BridgeBio can show a significant reduction in EPS losses and positive revenue growth, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The market will closely watch EPS as it has been a consistent area of disappointment, and a positive surprise could shift sentiment.

What is the revenue outlook for the next quarter?

Revenue growth is critical for assessing the company's future prospects and ability to recover from recent losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for BridgeBio to narrow its EPS losses significantly this quarter, given recent advancements in its pipeline.

Supporting Evidence

Historically, the company has shown an ability to surprise positively on earnings despite recent misses.

Options pricing suggests a lower expected move than the historical average, indicating potential for a larger reaction.

Insider buying activity could signal confidence in the company's recovery potential.

Key Risk

If the company reports an EPS loss below $0.70, it could shift the narrative significantly, challenging the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce or challenge the company's growth narrative amidst recent financial setbacks.

Bull Confirmed If

An EPS loss of less than $0.70 would indicate a significant improvement in financial performance.

Bear Confirmed If

An EPS loss greater than $0.84 would confirm ongoing struggles and likely lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by around 1.48%, confirming a potential turnaround in performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline of approximately 1.48%, reinforcing negative sentiment and concerns about the company's trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their therapies and any partnerships.
4Guidance on future revenue expectations and potential catalysts.
5Responses to analyst questions regarding the company's long-term strategy.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing innovative therapies for genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and meet market demand.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1-2026, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BridgeBio can show a significant reduction in EPS losses and positive revenue growth, it could signal a turnaround, boosting investor confidence.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The market will closely watch EPS as it has been a consistent area of disappointment, and a positive surprise could shift sentiment.

What is the revenue outlook for the next quarter?

Revenue growth is critical for assessing the company's future prospects and ability to recover from recent losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for BridgeBio to narrow its EPS losses significantly this quarter, given recent advancements in its pipeline.

Supporting Evidence

Historically, the company has shown an ability to surprise positively on earnings despite recent misses.

Options pricing suggests a lower expected move than the historical average, indicating potential for a larger reaction.

Insider buying activity could signal confidence in the company's recovery potential.

Key Risk

If the company reports an EPS loss below $0.70, it could shift the narrative significantly, challenging the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce or challenge the company's growth narrative amidst recent financial setbacks.

Bull Confirmed If

An EPS loss of less than $0.70 would indicate a significant improvement in financial performance.

Bear Confirmed If

An EPS loss greater than $0.84 would confirm ongoing struggles and likely lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by around 1.48%, confirming a potential turnaround in performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline of approximately 1.48%, reinforcing negative sentiment and concerns about the company's trajectory.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their therapies and any partnerships.
4Guidance on future revenue expectations and potential catalysts.
5Responses to analyst questions regarding the company's long-term strategy.